Skip to main content
News Nöthen 05.2021
Prof. Dr. Markus M. Nöthen (left) - and Jun.-Prof. Dr. Andreas Forstner (right) from the Institute of Human Genetics at the University Hospital Bonn
© Andrea Stein / UKB

News categories: Publication

Largest genetic study to date on bipolar disorder

In cooperation with the University of Bonn, researchers studied a total of 400,000 people

Genetic factors contribute significantly to the development of bipolar disorder. The probably largest analysis to date on the hereditary factors involved has now been published. More than 40,000 affected individuals and 370,000 controls were included in the study; some 320 researchers around the globe were involved. Lead partners for the project included the Icahn School of Medicine, New York, the University of Oslo and the University Hospital Bonn. The results not only provide new insights into the genetic basis of the disease, but also into possible risk factors in living conditions or behavior. They are published in the journal "Nature Genetics".

The name "bipolar disorder" is not a coincidence: The mood of those affected oscillates between two extremes. Sometimes they are so depressed for weeks that they barely manage to go about their daily activities. At other times, there are phases when they feel euphoric and full of energy, frantically pursuing their projects.

Risk factors include early childhood traumas such as abuse or the loss of a parent, but also, for example, a stressful lifestyle or the use of certain drugs. To a large extent, however, bipolar disorder is a matter of genes: Experts estimate the contribution of genetic makeup at 60 to 85 percent. Hundreds of genes are probably involved.

DNA lexicon compared at hundreds of thousands of sites

This greatly improves the understanding of the genetic basis. The international consortium searched the DNA of more than 400,000 participants for abnormalities. By comparing the DNA of their subjects at many hundreds of thousands of sites that occur variably in the population, they were able to identify genetic regions that are thought to contribute to the disease. "In this way, we identified 64 gene loci associated with bipolar disorder," explains Prof. Dr. Markus Nöthen, head of the Institute of Human Genetics and meme of the Cluster of Excellence ImmunoSensation2. "33 of them were previously unknown." The hits thus also provide clues to new therapeutic approaches.

Publication

Niamh Mullins, Andreas J. Forstner et al.: Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, DOI: 10.1038/s41588-021-00857-4

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview